Compare ABUS & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABUS | THFF |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 930.9M |
| IPO Year | 2008 | 1995 |
| Metric | ABUS | THFF |
|---|---|---|
| Price | $4.69 | $74.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 4.7M | 90.6K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | 55.26 | ★ 67.00 |
| EPS | 0.84 | ★ 3.58 |
| Revenue | ★ $14,083,000.00 | N/A |
| Revenue This Year | N/A | $17.88 |
| Revenue Next Year | $239.71 | $4.03 |
| P/E Ratio | ★ $5.71 | $20.73 |
| Revenue Growth | ★ 128.21 | N/A |
| 52 Week Low | $3.50 | $51.21 |
| 52 Week High | $5.45 | $84.17 |
| Indicator | ABUS | THFF |
|---|---|---|
| Relative Strength Index (RSI) | 37.59 | 32.39 |
| Support Level | $4.42 | $64.54 |
| Resistance Level | $4.81 | $75.61 |
| Average True Range (ATR) | 0.09 | 1.58 |
| MACD | -0.05 | -0.26 |
| Stochastic Oscillator | 16.48 | 2.39 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.